ONTX - Onconova Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 512.9M
Enterprise Value 37.01M
Trailing P/E N/A
Forward P/E 1-0.74
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)5.68
Price/Book (mrq)N/A
Enterprise Value/Revenue 33.09
Enterprise Value/EBITDA 6-0.31

Trading Information

Stock Price History

Beta (3Y Monthly) 3.50
52-Week Change 3-63.25%
S&P500 52-Week Change 3-0.33%
52 Week High 311.1700
52 Week Low 31.6900
50-Day Moving Average 32.5177
200-Day Moving Average 33.3475

Share Statistics

Avg Vol (3 month) 330.32k
Avg Vol (10 day) 324.24k
Shares Outstanding 55.89M
Float 3.96M
% Held by Insiders 14.76%
% Held by Institutions 159.20%
Shares Short (Jul 31, 2019) 4396.32k
Short Ratio (Jul 31, 2019) 415.93
Short % of Float (Jul 31, 2019) 410.77%
Short % of Shares Outstanding (Jul 31, 2019) 46.61%
Shares Short (prior month Jun 28, 2019) 4468.54k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 215/1
Last Split Date 3Sep 26, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-996.65%

Management Effectiveness

Return on Assets (ttm)-72.89%
Return on Equity (ttm)-389.83%

Income Statement

Revenue (ttm)2.27M
Revenue Per Share (ttm)0.39
Quarterly Revenue Growth (yoy)316.90%
Gross Profit (ttm)1.23M
EBITDA -22.58M
Net Income Avi to Common (ttm)-22.16M
Diluted EPS (ttm)-3.8180
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)5.88M
Total Cash Per Share (mrq)0.98
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.96
Book Value Per Share (mrq)-0.76

Cash Flow Statement

Operating Cash Flow (ttm)-24.07M
Levered Free Cash Flow (ttm)-16.11M